Abstract

BackgroundDownregulation of Aldolase B (ALDOB) has been reported in hepatocellular carcinoma. However, its clinical significance and its role in pathogenesis of HCC remain largely unknown.MethodsWe analyzed the expression of ALDOB and its clinical features in a large cohort of 313 HCC patients using tissue microarray and immunohistochemistry. Moreover, the function of stably overexpressed ALDOB in HCC cells was explored in vitro and in vivo. Gene expression microarray analysis was performed on ALDOB-overexpressing SMMC7721 cells to elucidate its mechanism of action.ResultsALDOB downregulation in HCC was significantly correlated with aggressive characteristics including absence of encapsulation, increased tumor size (>5 cm) and early recurrence. ALDOB downregulation was indicative of a shorter recurrence-free survival (RFS) and overall survival (OS) for all HCC patients and early-stage HCC patients (BCLC 0-A and TNM I stage patients). Multiple analyses revealed that ALDOB downregulation was an independent risk factor of RFS and OS. Stable expression of ALDOB in HCC cell lines reduced cell migration in vitro and inhibited lung metastasis, intrahepatic metastasis, and reduced circulating tumor cells in vivo. Mechanistically, we found that cells stably expressing ALDOB show elevated Ten–Eleven Translocation 1 (TET1) expression. Moreover, ALDOB expressing cells have higher levels of methylglyoxal than do control cells, which can upregulate TET1 expression.ConclusionThe downregulation of ALDOB could indicate a poor prognosis for HCC patients, and therefore, ALDOB might be considered a prognostic biomarker for HCC, especially at the early stage. In addition, ALDOB inhibits the invasive features of cell lines partly through TET1 expression.Electronic supplementary materialThe online version of this article (doi:10.1186/s12943-015-0437-7) contains supplementary material, which is available to authorized users.

Highlights

  • Downregulation of Aldolase B (ALDOB) has been reported in hepatocellular carcinoma

  • We found that its expression was further reduced in metastasis-inclined Hepatocellular carcinoma (HCC) (MIH) as compared to metastasis-averse HCC (MAH) (Fig. 1a)

  • We found that the mRNA level of ALDOB was significantly downregulated in most HCC tissues (Fig. 1b)

Read more

Summary

Introduction

Downregulation of Aldolase B (ALDOB) has been reported in hepatocellular carcinoma. Its clinical significance and its role in pathogenesis of HCC remain largely unknown. Aldolase B (ALDOB), known as fructosebisphosphate aldolase, is an important enzyme for glucose and fructose metabolism. Results from studies using different technologies but small sample sizes have shown that both ALDOB mRNA and protein are dramatically downregulated in HCC as compared to adjacent non-cancerous liver tissue [10,11,12,13,14]. The clinical significance of ALDOB and its role in the pathogenesis of HCC remain largely unknown

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call